Analytical Data
-
Gene name
MT3
- Application
-
Alternative Names
MT3;Metallothionein-3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25713
-
Expression Region
1-68aa
-
AA Sequence
MDPETCPCPSGGSCTCADSCKCEGCKCTSCKKSCCSCCPAECEKCAKDCV CKGGEAAEAEAEKCSCCQ
-
Molecular Weight
23 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of MT3 (Metallothionein-3) recombinant protein is situated at the intersection of molecular biology and neurobiology, primarily due to its unique properties and potential therapeutic implications. Metallothioneins are a family of metal-binding proteins involved in cellular metal ion homeostasis and protection against oxidative stress, with MT3 being predominantly expressed in the brain. Unlike its counterparts MT1 and MT2, MT3 is believed to play critical roles in neuronal function and development, including neuroprotection, modulation of neurotransmitter release, and involvement in neurodegenerative diseases. Research indicates that altered expression of MT3 may be linked to conditions such as Alzheimer's and schizophrenia, making it a promising biomarker for neurological disorders. Additionally, understanding the structural and functional attributes of MT3 can facilitate the development of recombinant protein techniques aimed at producing MT3 for experimental applications, such as assessing its neuroprotective capabilities in vitro and in vivo. The exploration of recombinant MT3 is essential for elucidating its mechanistic roles in brain physiology and pathology, opening avenues for novel therapeutic approaches to treat neurodegenerative diseases and enhance brain health.
